Top ▲

Guide to IMMUNOPHARMACOLOGY - Further Reading

This further reading collection is extracted from an open CiteUlike collection compiled by the curation team The papers presented are general, not ones we have curated database entries from since those papers are now referenced in the database (with the exception of review articles that include ligand structures). As can be seen these are mostly review articles that are relevant to the scope of the database. We would be pleased to receive recommendations for additions (either to this list or for curation).


  • Toll-like Receptors and the Control of Immunity.
    Fitzgerald KA, Kagan JC. (2020)
    Cell, 180 (6): 1044-1066. [PMID:32164908]

  • Neuroimmune Connections in Aging and Neurodegenerative Diseases.
    Scheiblich H, Trombly M, Ramirez A, Heneka MT. (2020)
    Trends Immunol, 41 (4): 300-312. [PMID:32147113]

  • Siglecs as Immune Cell Checkpoints in Disease.
    Duan S, Paulson JC. (2020)
    Annu Rev Immunol, 38: 365-395. [PMID:31986070]

  • Targeting macrophages: therapeutic approaches in cancer.
    Cassetta L, Pollard JW. (2018)
    Nat Rev Drug Discov, 17 (12): 887-904. [PMID:30361552]

  • Regulatory T cells in the treatment of disease.
    Sharabi A, Tsokos MG, Ding Y, Malek TR, Klatzmann D, Tsokos GC. (2018)
    Nat Rev Drug Discov, 17 (11): 823-844. [PMID:30310234]

  • Cardioimmunology: the immune system in cardiac homeostasis and disease.
    Swirski FK, Nahrendorf M. (2018)
    Nat Rev Immunol, 18 (12): 733-744. [PMID:30228378]

  • Impact of oncogenic pathways on evasion of antitumour immune responses.
    Spranger S, Gajewski TF. (2018)
    Nat Rev Cancer, 18 (3): 139-147. [PMID:29326431]

  • Hitting the Target: How T Cells Detect and Eliminate Tumors.
    Zamora AE, Crawford JC, Thomas PG. (2018)
    J Immunol, 200 (2): 392-399. [PMID:29311380]

  • A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.
    Finn OJ. (2018)
    J Immunol, 200 (2): 385-391. [PMID:29311379]

  • Checkpoints in TNF-Induced Cell Death: Implications in Inflammation and Cancer.
    Annibaldi A, Meier P. (2018)
    Trends Mol Med, 24 (1): 49-65. [PMID:29217118]

  • Immune-pineal axis - acute inflammatory responses coordinate melatonin synthesis by pinealocytes and phagocytes.
    Markus RP, Fernandes PA, Kinker GS, da Silveira Cruz-Machado S, Marçola M. (2018)
    Br J Pharmacol, 175 (16): 3239-3250. [PMID:29105727]

  • The spectrum of T cell metabolism in health and disease.
    Bantug GR, Galluzzi L, Kroemer G, Hess C. (2018)
    Nat Rev Immunol, 18 (1): 19-34. [PMID:28944771]

  • Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?.
    Baker KF, Isaacs JD. (2018)
    Ann Rheum Dis, 77 (2): 175-187. [PMID:28765121]

  • Mechanisms and Consequences of Defective Efferocytosis in Atherosclerosis.
    Yurdagul Jr A, Doran AC, Cai B, Fredman G, Tabas IA. (2017)
    Front Cardiovasc Med, 4: 86. [PMID:29379788]

  • Current insights into the role of human β-defensins in atopic dermatitis.
    Chieosilapatham P, Ogawa H, Niyonsaba F. (2017)
    Clin Exp Immunol, 190 (2): 155-166. [PMID:28708318]

  • Innate Immune Function of Mitochondrial Metabolism.
    Sancho D, Enamorado M, Garaude J. (2017)
    Front Immunol, 8: 527. [PMID:28533780]

  • Novel aspects of defensins' involvement in virus-induced autoimmunity in the central nervous system.
    Kazakos EI, Kountouras J, Polyzos SA, Deretzi G. (2017)
    Med Hypotheses, 102: 33-36. [PMID:28478826]

  • Mitochondria are the powerhouses of immunity.
    Mills EL, Kelly B, O'Neill LAJ. (2017)
    Nat Immunol, 18 (5): 488-498. [PMID:28418387]

  • Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis.
    Foks AC, Kuiper J. (2017)
    Br J Pharmacol, 174 (22): 3940-3955. [PMID:28369782]

  • Biased agonism and allosteric modulation of G protein-coupled receptor 183 - a 7TM receptor also known as Epstein-Barr virus-induced gene 2.
    Daugvilaite V, Madsen CM, Lückmann M, Echeverria CC, Sailer AW, Frimurer TM, Rosenkilde MM, Benned-Jensen T. (2017)
    Br J Pharmacol, 174 (13): 2031-2042. [PMID:28369721]

  • Immunology proves a great success for treating systemic autoimmune diseases - a perspective on immunopharmacology: IUPHAR Review 23.
    Ishii M. (2017)
    Br J Pharmacol, 174 (13): 1875-1880. [PMID:28299772]

  • New checkpoints in cancer immunotherapy.
    Ni L, Dong C. (2017)
    Immunol Rev, 276 (1): 52-65. [PMID:28258699]

  • The role of genomics in common variable immunodeficiency disorders.
    Kienzler AK, Hargreaves CE, Patel SY. (2017)
    Clin Exp Immunol, 188 (3): 326-332. [PMID:28236292]

  • Mechanisms of immunomodulation by mammalian and viral decoy receptors: insights from structures.
    Felix J, Savvides SN. (2017)
    Nat Rev Immunol, 17 (2): 112-129. [PMID:28028310]

  • It's a lot of work to be nonallergic.
    Sette A, Schulten V. (2017)
    J Allergy Clin Immunol, 139 (3): 769-770. [PMID:27993537]

  • PI3Kδ and primary immunodeficiencies.
    Lucas CL, Chandra A, Nejentsev S, Condliffe AM, Okkenhaug K. (2016)
    Nat Rev Immunol, 16 (11): 702-714. [PMID:27616589]

  • Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents.
    Kopalli SR, Kang TB, Koppula S. (2016)
    Expert Opin Ther Pat, 26 (11): 1239-1256. [PMID:27568917]

  • Regulatory circuits of T cell function in cancer.
    Speiser DE, Ho PC, Verdeil G. (2016)
    Nat Rev Immunol, 16 (10): 599-611. [PMID:27526640]

  • Clinical significance of T cell metabolic reprogramming in cancer.
    Herbel C, Patsoukis N, Bardhan K, Seth P, Weaver JD, Boussiotis VA. (2016)
    Clin Transl Med, 5 (1): 29. [PMID:27510264]

  • A guide to immunometabolism for immunologists.
    O'Neill LA, Kishton RJ, Rathmell J. (2016)
    Nat Rev Immunol, 16 (9): 553-65. [PMID:27396447]

  • Combinatorial antibody libraries: new advances, new immunological insights.
    Lerner RA. (2016)
    Nat Rev Immunol, 16 (8): 498-508. [PMID:27374636]

  • Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies.
    Hasan M, Yan N. (2016)
    Pharmacol Res, 111: 336-42. [PMID:27353409]

  • Peripheral Immune Cell Populations Associated with Cognitive Deficits and Negative Symptoms of Treatment-Resistant Schizophrenia.
    Fernandez-Egea E, Vértes PE, Flint SM, Turner L, Mustafa S, Hatton A, Smith KG, Lyons PA, Bullmore ET. (2016)
    PLoS ONE, 11 (5): e0155631. [PMID:27244229]

  • Trained immunity: A program of innate immune memory in health and disease.
    Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, O'Neill LA, Xavier RJ. (2016)
    Science, 352 (6284): aaf1098. [PMID:27102489]

  • Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations.
    Hoos A. (2016)
    Nat Rev Drug Discov, 15 (4): 235-47. [PMID:26965203]

  • Cannabinoids and autoimmune diseases: A systematic review.
    Katchan V, David P, Shoenfeld Y. (2016)
    Autoimmun Rev, 15 (6): 513-28. [PMID:26876387]

  • Immunometabolism governs dendritic cell and macrophage function.
    O'Neill LA, Pearce EJ. (2016)
    J Exp Med, 213 (1): 15-23. [PMID:26694970]

  • Inflammaging and Anti-Inflammaging: The Role of Cytokines in Extreme Longevity.
    Minciullo PL, Catalano A, Mandraffino G, Casciaro M, Crucitti A, Maltese G, Morabito N, Lasco A, Gangemi S, Basile G. (2016)
    Arch Immunol Ther Exp (Warsz.), 64 (2): 111-26. [PMID:26658771]

  • Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17.
    Landolina N, Levi-Schaffer F. (2016)
    Br J Pharmacol, 173 (5): 793-803. [PMID:26620589]

  • Role of neutrophils in atherogenesis: an update.
    Pende A, Artom N, Bertolotto M, Montecucco F, Dallegri F. (2016)
    Eur J Clin Invest, 46 (3): 252-63. [PMID:26573245]

  • Combination cancer immunotherapy and new immunomodulatory targets.
    Mahoney KM, Rennert PD, Freeman GJ. (2015)
    Nat Rev Drug Discov, 14 (8): 561-84. [PMID:26228759]

  • The life (and death) of CD4+ CD28(null) T cells in inflammatory diseases.
    Dumitriu IE. (2015)
    Immunology, 146 (2): 185-93. [PMID:26190355]

  • Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
    Pico de Coaña Y, Choudhury A, Kiessling R. (2015)
    Trends Mol Med, 21 (8): 482-91. [PMID:26091825]

  • Regulation of tumour necrosis factor signalling: live or let die.
    Brenner D, Blaser H, Mak TW. (2015)
    Nat Rev Immunol, 15 (6): 362-74. [PMID:26008591]

  • Ion channels in innate and adaptive immunity.
    Feske S, Wulff H, Skolnik EY. (2015)
    Annu Rev Immunol, 33: 291-353. [PMID:25861976]

  • TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future.
    Sedger LM, McDermott MF. (2014)
    Cytokine Growth Factor Rev, 25 (4): 453-72. [PMID:25169849]

  • Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.
    Du Pasquier RA, Pinschewer DD, Merkler D. (2014)
    CNS Drugs, 28 (6): 535-58. [PMID:24723124]

  • Immunologic therapeutics and psychotic disorders.
    Bullmore ET, Lynall ME. (2014)
    Biol Psychiatry, 75 (4): 260-1. [PMID:24439554]

  • Mast cells, glia and neuroinflammation: partners in crime?.
    Skaper SD, Facci L, Giusti P. (2014)
    Immunology, 141 (3): 314-27. [PMID:24032675]

  • Immune-Pineal Axis: Nuclear Factor κB (NF-kB) Mediates the Shift in the Melatonin Source from Pinealocytes to Immune Competent Cells.
    Markus RP, Cecon E, Pires-Lapa MA. (2013)
    Int J Mol Sci, 14 (6): 10979-97. [PMID:23708099]

  • The atypical PKCs in inflammation: NF-κB and beyond.
    Diaz-Meco MT, Moscat J. (2012)
    Immunol Rev, 246 (1): 154-67. [PMID:22435553]

  • Humanized mice for modeling human infectious disease: challenges, progress, and outlook.
    Legrand N, Ploss A, Balling R, Becker PD, Borsotti C, Brezillon N, Debarry J, de Jong Y, Deng H, Di Santo JP et al.. (2009)
    Cell Host Microbe, 6 (1): 5-9. [PMID:19616761]

Other Reading

  • Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans.
    Hu Y, Ranganathan M, Shu C, Liang X, Ganesh S, Osafo-Addo A, Yan C, Zhang X, Aouizerat BE, Krystal JH et al.. (2020)
    Sci Rep10 (1): 3450. [PMID:32103029]

  • Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy?.
    Lütje S, Feldmann G, Essler M, Brossart P, Bundschuh RA. (2020)
    J Nucl Med61 (8): 1137-1144. [PMID:31924724]

  • Analysis of the B cell receptor repertoire in six immune-mediated diseases.
    Bashford-Rogers RJM, Bergamaschi L, McKinney EF, Pombal DC, Mescia F, Lee JC, Thomas DC, Flint SM, Kellam P, Jayne DRW et al.. (2019)
    Nature574 (7776): 122-126. [PMID:31554970]

  • Gene Regulatory Programs Conferring Phenotypic Identities to Human NK Cells.
    Collins PL, Cella M, Porter SI, Li S, Gurewitz GL, Hong HS, Johnson RP, Oltz EM, Colonna M. (2019)
    Cell176 (1-2): 348-360.e12. [PMID:30595449]

  • Epigenetic control of innate and adaptive immune memory.
    Lau CM, Adams NM, Geary CD, Weizman OE, Rapp M, Pritykin Y, Leslie CS, Sun JC. (2018)
    Nat Immunol19 (9): 963-972. [PMID:30082830]

  • Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice.
    Jung KH, Yoo W, Stevenson HL, Deshpande D, Shen H, Gagea M, Yoo SY, Wang J, Eckols TK, Bharadwaj U et al.. (2017)
    Clin Cancer Res23 (18): 5537-5546. [PMID:28533225]

  • Inhibition of KDM4A activity as a strategy to suppress interleukin-6 production and attenuate colitis induction.
    Ishiguro K, Watanabe O, Nakamura M, Yamamura T, Matsushita M, Goto H, Hirooka Y. (2017)
    Clin Immunol180: 120-127. [PMID:28511912]

  • Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity.
    Soethoudt M, Grether U, Fingerle J, Grim TW, Fezza F, de Petrocellis L, Ullmer C, Rothenhäusler B, Perret C, van Gils N et al.. (2017)
    Nat Commun8: 13958. [PMID:28045021]

  • Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
    Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, Furniss M, Vaughan R, Christiano AM, Clynes R. (2016)
    JCI Insight1 (15): e89790. [PMID:27699253]

  • PI3Kγ is a molecular switch that controls immune suppression.
    Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, Woo G, Nguyen AV, Figueiredo CC, Foubert P et al.. (2016)
    Nature539 (7629): 437-442. [PMID:27642729]

  • Intestinal Epithelial Cell-Intrinsic Deletion of Setd7 Identifies Role for Developmental Pathways in Immunity to Helminth Infection.
    Oudhoff MJ, Antignano F, Chenery AL, Burrows K, Redpath SA, Braam MJ, Perona-Wright G, Zaph C. (2016)
    PLoS Pathog12 (9): e1005876. [PMID:27598373]

  • Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis.
    Koopman FA, Chavan SS, Miljko S, Grazio S, Sokolovic S, Schuurman PR, Mehta AD, Levine YA, Faltys M, Zitnik R et al.. (2016)
    Proc Natl Acad Sci USA113 (29): 8284-9. [PMID:27382171]

  • A human and animal model-based approach to investigating the anti-inflammatory profile and potential of the 5-HT2B receptor antagonist AM1030.
    Palmqvist N, Siller M, Klint C, Sjödin A. (2016)
    J Inflamm (Lond.)13: 20. [PMID:27340371]

  • Transcriptomics in Interferon-α-Treated Patients Identifies Inflammation-, Neuroplasticity- and Oxidative Stress-Related Signatures as Predictors and Correlates of Depression.
    Hepgul N, Cattaneo A, Agarwal K, Baraldi S, Borsini A, Bufalino C, Forton DM, Mondelli V, Nikkheslat N, Lopizzo N et al.. (2016)
    Neuropsychopharmacology41 (10): 2502-11. [PMID:27067128]

  • Notch Antagonists: Potential Modulators of Cancer and Inflammatory Diseases.
    Kumar R, Juillerat-Jeanneret L, Golshayan D. (2016)
    J Med Chem59 (17): 7719-37. [PMID:27045975]

  • SOCS2: physiological and pathological functions.
    Letellier E, Haan S. (2016)
    Front Biosci (Elite Ed)8: 189-204. [PMID:26709655]

  • What is the evidence for the role of TRP channels in inflammatory and immune cells?.
    Parenti A, De Logu F, Geppetti P, Benemei S. (2016)
    Br J Pharmacol173 (6): 953-69. [PMID:26603538]

  • CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.
    Hayes GM, Cairns B, Levashova Z, Chinn L, Perez M, Theunissen JW, Liao-Chan S, Bermudez A, Flory MR, Schweighofer KJ et al.. (2015)
    Am J Transl Res7 (6): 1181-8. [PMID:26279761]

  • Activation of protease‑activated receptor‑2 is associated with increased expression of inflammatory factors in the adipose tissues of obese mice.
    Li M, Yang X, Zhang Y, Chen L, Lu H, Li X, Yin L, Zhi X. (2015)
    Mol Med Rep12 (4): 6227-34. [PMID:26252901]

  • Kinase inhibition, competitive binding and proteasomal degradation: resolving the molecular function of the suppressor of cytokine signaling (SOCS) proteins.
    Linossi EM, Nicholson SE. (2015)
    Immunol Rev266 (1): 123-33. [PMID:26085211]

  • Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer.
    Mancini M, Gaborit N, Lindzen M, Salame TM, Dall'Ora M, Sevilla-Sharon M, Abdul-Hai A, Downward J, Yarden Y. (2015)
    Sci Signal8 (379): ra53. [PMID:26038598]

  • Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity.
    Jacobsen HJ, Poulsen TT, Dahlman A, Kjær I, Koefoed K, Sen JW, Weilguny D, Bjerregaard B, Andersen CR, Horak ID et al.. (2015)
    Clin Cancer Res21 (18): 4110-22. [PMID:25908781]

  • Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases.
    Irani V, Guy AJ, Andrew D, Beeson JG, Ramsland PA, Richards JS. (2015)
    Mol Immunol67 (2 Pt A): 171-82. [PMID:25900877]

  • Gene delivery of suppressors of cytokine signaling (SOCS) inhibits inflammation and atherosclerosis development in mice.
    Recio C, Oguiza A, Mallavia B, Lazaro I, Ortiz-Muñoz G, Lopez-Franco O, Egido J, Gomez-Guerrero C. (2015)
    Basic Res Cardiol110 (2): 8. [PMID:25604439]

  • L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia.
    Rosilio C, Nebout M, Imbert V, Griessinger E, Neffati Z, Benadiba J, Hagenbeek T, Spits H, Reverso J, Ambrosetti D et al.. (2015)
    Leukemia29 (6): 1253-66. [PMID:25482130]

  • Effect of the aspartic acid D2 on the affinity of Polybia-MP1 to anionic lipid vesicles.
    Leite NB, Dos Santos Alvares D, de Souza BM, Palma MS, Ruggiero Neto J. (2014)
    Eur Biophys J43 (4-5): 121-30. [PMID:24595375]

  • Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion.
    Häusler SF, Del Barrio IM, Diessner J, Stein RG, Strohschein J, Hönig A, Dietl J, Wischhusen J. (2014)
    Am J Transl Res6 (2): 129-39. [PMID:24489992]

  • Regulation of Janus kinases by SOCS proteins.
    Kershaw NJ, Murphy JM, Lucet IS, Nicola NA, Babon JJ. (2013)
    Biochem Soc Trans41 (4): 1042-7. [PMID:23863176]

  • Group 2 innate lymphoid cells show up in the skin.
    Spits H. (2013)
    Immunol Cell Biol91 (6): 390-2. [PMID:23732616]

  • Type 2 innate lymphoid cells-new members of the "type 2 franchise" that mediate allergic airway inflammation.
    Mjösberg J, Spits H. (2012)
    Eur J Immunol42 (5): 1093-6. [PMID:22539283]

  • The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation.
    Pavlov VA, Wang H, Czura CJ, Friedman SG, Tracey KJ. (2003)
    Mol Med9 (5-8): 125-34. [PMID:14571320]